

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of
Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.



WO 01/97850 A2

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30 A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine


kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I




in which

r has the meaning of 0 to 2,

n has the meaning of 0 to 2;


R_3 und R_4 a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and
has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the
meaning of nitrogen, and each others have the meaning of
CH, and the bining is via the atoms T_1 and T_4 ;

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or
 $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkeny-
lene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$,
 $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$,
 $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

independently from each other have the meaning of N or CH ,
with the provisio that not more than three of these
Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogene, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
10 esterificated hydroxy, nitro, cyano, carboxy, esterificated
carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one ore more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranyl acid derivatives of general formula IV

30



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

5

X

Y

p

R¹

10

15

R²

20

R³

25

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,


has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




V,


in which

R¹ has the meaning of group


20




14



in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,




in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

10 The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

5 Combined functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefore the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector
15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

	mode of treatment	
treatment group	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

 R_3 und R_4

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms, and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


25 30 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

43

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygene atom,
 or a salt thereof,

and/or a compound of general formula IV


5



in which

- 10 A has the meaning of group $=NR^2$,
 W has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,
 Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$
 $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	$R_a, R_b, R_c, R_d, R_e, R_f$	independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,
10	X	has the meaning of group $=NR^9$ or $=N-$,
	Y	has the meaning of group $-(CH_2)_p$,
	p	has the meaning of integer 1-4,
15	R^1	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R^2	has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,
25	R^3	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7


substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,
independently from each other have the meaning
of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl
or C_{1-6} -carboxyalkyl, which are unsubstituted or
optionally substituted with one or more of
halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning
of hydrogen or C_{1-6} -alkyl,
as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R^1 has the meaning of group

46




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,




in which R^8 is -CH₃, fluoro,
chloro or -CF₃

in which R^4 is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R^6 is
-CH₃ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-
yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not
identically to compound II.

18. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

```

ttttacagtt ttccttttct tcagagttta ttttgaattt tcattttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaca gccaaaaaac cataatgggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaaccacac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaagggggt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctacagcggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaacc ccaaaacgca acctaaccac agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcattttaatg ttaaacgcca tcaggggcct ctctcccgt 1320
ttctgccagg ggtttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcct tctggctgct tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgaccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtcccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggctcttcc tgctgggtgct 1620
cttggacggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60
 acactaacia cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacia agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttagggcct 540
 cacctcccca tgacatctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

25 tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcac tgcaggctctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcacaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcatg 480
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

40 cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctgggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggg cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcagggtg 360
 ctgcgtggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgca gaacactggc gacatagggt cccatcagtg 480
 ctccgcggat ggcagggcga ccactctctg ccaccgagat cttggccatc tgacgctcta 540
 cgcccgccag cgcccgtctc acctgtgggt ccttggccgg cagtgcgccg agctccccct 600
 50 ccttctgccc cagccgtctt tctcgccgag acaggtaa atgacatggccc aggtagacca 660
 ggggtgggtgt gctgacgaag aggaactgca gcaccagta gcggatgtgg gagatgggga 720
 aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctctggacc tggccagca 900
 55 acttctccac gaagccccag tcaccatgg ctcccgggccc tccgtcggca aggagacaga 960
 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcaggag 1020
 gtctgccacg cccgttctac cgctgcctg ccgggcggcc cagggtggagg tggggacgat 1080
 ggccggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgct	ttttgaaaat	gttgagggtg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaagtg	gggccagggc	240
5	ccagacccaa	gaggagaggg	tgggtccgcag	acacccccgg	atgtcagcat	cccccgacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgctg	ggaacagggg	gcagggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatgggtg	caggacaggt	480
	gtcccttcag	tcctctgggt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
10	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttgcttttat	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggccgtgca	720
	ctgggcaggc	ttctctgtag	aacccagggg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
15	accaaaggcc	tcctgttctg	ttatttctct	taaatcaaca	tgctattttg	ttttcactca	900
	cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctggtggtg	agcagggagc	gtgcaccgga	cggcgggata	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcggggcgg	gggcagctct	cggggctgct	120
	ggtattacct	gcgctacttc	tctctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtcc	aacctgcagg	240
30	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gcctcccagt	300
	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgcag	ctggaccgca	tcaatgccag	cttccgccag	tgccaggggtg	420
	accgggtcat	ctacacgaac	aatcagagggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttctgct	ttcatgctga	540
35	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
	ataaggaaag	cgtgctgctg	aacaaacgcg	tggcggagga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtgca	720
	agccctctgc	ctgcccctgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
40	ctcgggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
	ggtggaggag	ctggcccggg	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tgggaagcca	gcagggcctg	cggggccagtc	aggaggcgaa	1020
	acagaagggtg	gagaaggagg	ctcaggcccc	ggaggccaag	ctccaagctg	aatgctcccg	1080
	gcagacccag	ctagcgtggt	aggagaaggc	ggtgctgcgg	aagggaacgag	acaacctggc	1140
45	caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tggccatcag	1200
	aaactcagcc	ctggacacct	gcataagac	caagtgcag	ccgatgatgc	cagtgtcaag	1260
	gcccatgggc	cctgtcccca	acccccagcc	catcgaccca	gctagcctgg	aggagttcaa	1320
	gaggaagatc	ctggagtccc	agaggccccc	tgcaggcata	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccgaggat	1440
50	gcagggatat	gctcacagcg	cccagacaaa	ccccctccc	ccgcccccaa	ccaccaggg	1500
	ccaccatcag	acaactccct	gcatacaaac	ccctagtacc	ctctcacacc	cgcaccgcg	1560
	cctcacgata	cctcacccag	agcacacggc	cgcgagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcaccgt	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
55	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
	tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgtcacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatatggcac	caacatcaca	tgacgcgatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacggggcca	aggtacccac	aggatcccat	ccccctccc	acagccctgg	gccccagcac	2040
	ctccccctct	ccagcttcct	ggcctcccag	ccacttctct	acccccagtg	cctggacccc	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtgttt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggggtc	cctgttgtcg	ggaggggagc	cactccttct	2220
	cccccaactc	ccagccctgc	ctgtggcccc	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						

<212> DNA
<213> Human

<400> 7

5

10

```
gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atattgggtc gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc
```

<210> 8
<211> 157
<212> DNA
<213> Human

15

<400> 8

20

```
tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg
```

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

35

40

```
aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgata 480
ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a
```

<210> 10
<211> 1508
<212> DNA
<213> Human

45

<400> 10

50

55

60

65

```
cacaaacacg agagactcca cggtctgcct gagcacogcc agcctcctag gctccagcac 60
tcgcaggtec attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactct 240
gagctcaagc caggtgagct taagccactg agcaaggag atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacaac 480
tgtgtctgaca acccatgttc ttgcagccag tctcactggt gtacacgatg gtcagccatg 540
ggtgtcatgt ccctcttttt gccttgttta tgggtgttacc ttccagccaa gggttgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc cccctagga actttgaaaa accaacatag 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagttag gatagtcttt 840
gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaata ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaag tttttgtttg tgaatagtag ttgcaaaact 1020
```

5	tgtaaattag	cagatgactt	ttttccattg	ttttctccag	agagaatgtg	ctatatTTTT	1080
	gtatatacaa	taatatTTTgc	aactgtgaaa	aacaagtgg	gccatactac	atggcacaga	1140
	cacaaaatat	tatactaata	tgttgtagat	tcggaagaat	gtgaatcaat	cagtatgttt	1200
	ttagattgta	ttttgcctta	cagaaagcct	ttattgtaag	actctgattt	ccctttggac	1260
	ttcatgtata	ttgtacagtt	acagtaaaat	tcaaccttta	ttttctaatt	ttttcaacat	1320
	attgttttagt	gtaaagaata	tttatttgaa	gtttttattat	tttataaaaa	agaatatTTta	1380
	ttttaagagg	catcttacia	attttgcccc	ttttatgagg	atgtgatagt	tgctgcaaat	1440
	gaggggttac	agatgcatat	gtccaatata	aaatagaaaa	tatatTTaacg	tttgaaatta	1500
aaaaaaaa							
10	<210> 11						
	<211> 389						
	<212> DNA						
	<213> Human						
15	<400> 11						
	gggcaggtga	tcagggcaca	catttcccgt	ccattgagac	agtagcattc	ccggcaccca	60
	tcgtgccagc	tctcctcatt	tttatgatga	tgaccatcca	cgggtgagaca	agtgcgccgac	120
20	aggatgggtg	gcccagctga	agcacaggcc	gctctgcact	tgagataag	acagccgtga	180
	ctgtcctgct	ggaaacccaa	ggggcagatc	ttactgcatg	agagctctgg	acattttctta	240
	cagcgacaga	tgtcacagcc	gtgcttattc	ttcagcaatc	caagtggaca	atacttgtca	300
	cagatttatgg	gtctgcactt	cttgggcctt	gggcgggcact	cacagatctc	acagtTTttgg	360
	acctcgggccg	cgaccacgct	gggtaccga				
25	<210> 12						
	<211> 981						
	<212> DNA						
	<213> Human						
30	<400> 12						
	ttttttttttt	ttggattgca	aaaattttatt	aaaattggag	acactgtttt	aatctttcttg	60
	tgccatgaga	ctccatcagg	cagtctacia	agaccactgg	gaggctgagg	atcacttgag	120
35	cccagaagtt	tgaggctgta	gtaagcttca	aaggccactg	cactctagct	tggggtgaggc	180
	aagacccttt	caagcagtaa	gctgcatgct	tgcttgttgt	ggtcatttaa	aaccctagtt	240
	taggataaca	acatatTTaat	cagggcaaaa	tacaaatgtg	tgatgcttgt	tagtagagta	300
	acctcagaat	caaaatggaa	cggTTTTaca	gtgatatcat	tatatTTcat	ttggcagaat	360
	cattacatca	ttggTTacac	tgaaaatcat	cacatgtacc	aaaagctgac	tcacctagtt	420
	taggataaca	ggtctgcctg	tttgaagatg	aaaaataata	ccattTTtaa	atttgcccta	480
40	ctcaatttcc	ttctcagtca	cattTTtaact	TTtaaacagc	taatcactcc	catctacaga	540
	TTaaggTgta	tatgccacca	aaacctTTttg	ccaccttaaa	aatttcccttc	aaagtTTtaaa	600
	ctaattgcctg	catttcttca	atcatgaatt	ctgagtcctt	tgcttctTTta	aaacttgctc	660
	cacacagtgt	agtcaagccg	actctccata	cccaagcaag	tcattccatgg	ataaaaaacgt	720
	taccaggagc	agaaccatta	agctggTcca	ggcaagtTtg	actccaccat	ttcaacttcc	780
	agctTTtctgt	ctaattgcctg	tgtgccaatg	gcttgagtta	ggcttgctct	ttaggacttc	840
45	agtagctatt	ctcatccttc	cttggggaca	caactgtcca	taaggTgcta	tccagagcca	900
	cactgcatct	gcaccagca	ccatacctca	caggagtcca	ctcccacgag	ccgctgtat	960
	ataagagttc	ttttgatgac	g				
	<210> 13						
	<211> 401						
50	<212> DNA						
	<213> Human						
	<400> 13						
55	ataactacag	cttcagcaga	caactaaaga	gactgcatta	aggtgatttc	tctggctata	60
	aagagagccc	ggccgcagag	catgtgactg	ctgggacctc	tgggataggc	aacactgccc	120
	tctctcccc	agagcgaccc	cccgggcagg	tcggggccca	aggaatgacc	cagcaactgc	180
	tccctacce	gcacactctc	tttactgcca	cctgcaatta	tgctgtgaag	atgactgggt	240
	gtggtcatca	cgattcagag	aaatcaagat	ctatgaccat	tttaggcaaa	gagagaaact	300
	tggagaattg	ctgaggacta	ctgaaccttg	ttttgctttt	TTaaaaaata	ctaaatcctc	360
60	acttcagcat	atttagttgt	cattaaaatt	aagctgatat	t		
	<210> 14						

<211> 1002
<212> DNA
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
10 tttgaaaatg ttaaatacaa gtccctattct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaagggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa ccagttttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatgggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaagga gtagtaacca agcttttctg ccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
20 acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatc tggttaggtc aggagtggga acccaaatc aattctttta 960
acaaacacta aaggtgatc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

cgagggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tatcctatctt 60
ataatattcc tattctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
35 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgttagtggt tgtaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcattttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
50 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaaaaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
tagatatattg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac gagtctgccca actgtattaa atcctcctcc 780
acccctcca ccagttggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccgg gctcgagcat tcaactcttg 900
60 ttcctgtaaa tatagtattt tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
65 gtaaatagact ctgggaggat gctaattgcca gagcctcaga ctggtggtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtc	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	ccaaaaccag	tggccagtg	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgcata	1620
	gttttctcag	catttttgcag	agaggcacag	ttttcacaat	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttccacc	1740
	tcccgggttc	tgagggtacat	ctttattaac	agaatcttg	ttagattcgt	tagggacaga	1800
10	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggtttttt	cattcacaag	1860
	tgagtcacag	atgaaggcag	ctgttggttg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcat	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210> 17						
	<211> 235						
	<212> DNA						
	<213> Human						
20	<400> 17						
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccagggtgtg	cagcgaacaa	ctgtagtctc	120
25	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aaggttacag	180
	tggggccacga	tcattgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210> 18						
	<211> 2732						
	<212> DNA						
30	<213> Human						
	<400> 18						
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
35	tcattgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttgggtga	tcacattgtg	caaaatgggtg	aagcattcaa	acactttgaa	180
	accagattct	agcagggttg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggctcttctg	gttgcttttt	attaatgagg	agactattgt	300
40	gatggcatat	ctcttcacta	tatttaattgc	tttccaggga	gtgttcattt	tcctcttca	360
	ctgtgctctc	caaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctgc	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
45	tcaagggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
	catcttcaag	atttataatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaaggggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
50	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
	ctattgtggc	agatgcttca	tctttaattgc	acagcgacaa	cccagggctg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
55	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggagga	1260
	gtgagaatga	ggacatttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatgggtta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggccca	catgcgagta	ttaataaata	aagacaccat	1500
60	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtgggttctc	1560
	tgggtgtaaaa	aagatgactg	aaccttgacg	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattattttgt	tacaaagaaa	agagatgcca	1680
	gccaggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgcagttc	actgcaaata	ttttacatta	aggcaaagat	tgaaaacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatattt	ttctattgct	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgtcattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattacttac	attttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcacccct	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaac	2460
10	tttctagtga	acaaaaggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatatatta	gtaatttaatt	tatttttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gcccatacct	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtactttaga	60
	aaccgccttt	gcataattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctcccaact	gcatgcctca	agtccctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtggggcct	gcttcgcttt	tgaggggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggat	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atggggcggg	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atltgagatg	gcgattaacc	360
	ttgccaaagag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagtgtga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cacttttgatg	tggagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgcacatcat	gagtgggtacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
50	tgctttttga	gcaggcagag	agcaacatga	agcgctacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgatagggag	gccccaggct	gcaggggcaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
55	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggtcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatggtgt	cctttacctt	tatgagcagg	ggaagctgtt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtac	cggcagggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
60	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgtcatcagg	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccacccgt	atccgcccag	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtccact	1740
65	tcctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcggaa	agtgatgctg	1800
	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gccaggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

5	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaacagaca	caatgggacc	tggggcgggcg	ttacacagaa	ggctggctga	catgccccagg	2160
	gctccactct	catctaattgt	cacagccctc	acaagactaa	agcggaactt	tttctttttcc	2220
	ctggccttcc	ttaatttttaa	gtcaagcttg	gcaatccctt	cctcttttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atgggggggga	aggggaacct	caggcaaac	tcctgaagtt	2340
	ttggaaaaaa	aagctggttt	c				
10	<210> 21 <211> 179 <212> DNA <213> Human						
15	<400> 21						
20	aggtgtttaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattcttttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagtttagcc	cttgaacagc	120
	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210> 22 <211> 905 <212> DNA <213> Human						
25	<400> 22						
30	ttttttttttt	ttcttttaacc	gtgtggtctt	tattttcagtg	ccagtgtttac	agatacaaca	60
	caaatgttcc	agtttagaagg	aattcaaacg	gaatgccaag	gtccaagcca	ggctcaagaa	120
	ataaaaaggg	aggtttgagg	taatagataa	gatgactcca	atactcactc	ttcctaaggg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtgggtgggaa	300
	taggggtcatt	aataactatg	aatatatctt	ttagaagggtg	accatttttgc	acttttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaaag	420
	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatatc	cttcatgcca	480
	aatctcaaca	aaagctcttt	ttactccat	ctgtccagtg	tttacaaata	aactcgcaag	540
	gtctgaccag	ttcttggttaa	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaatgcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
	ggcagggctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagtg	720
40	cctgaagatg	gtaaccacagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgtgtcagag	acaaagttag	tgtttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccaggggaat	900
	gttga						
45	<210> 23 <211> 2134 <212> DNA <213> Human						
50	<400> 23						
55	ggctctcttct	ttccttttttt	tttttccaaa	agtgttcttt	tattttctagt	aacatatatt	60
	gtataaatac	tctatttttat	atgcacttcc	acaaaagcga	tataatttta	aagtttttttt	120
	cattagaaat	aaatgtataa	aaataaatat	gttatttatag	gcattttatta	ctaactatag	180
	tccttcttgg	aagggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tatttttacta	tatacatatg	gaaaaaatca	tatttctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctacccct	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
	tcattttttgt	tccggcgttt	catectcctt	gtgtgattgt	actgattttc	atgagacaca	480
	agttacttct	ttacatccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggaggtact	aagctcattg	tgtctcctct	agctttttacc	agcatctaat	gcttcactgc	600
	ttttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagttgt	tttttcctca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccattttgc	720
60	gttattttcac	gttgctgagc	ctttctctca	tgttgaaaca	tctgaagttt	taattctcgg	780
	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaag	840
	atcctatttg	tactcctttc	tccccccatt	gttaqtgagg	taaagtaaaa	caggtcttag	900
65							

	taaaatctca	cttttctcct	acttttcatt	tcccaacccc	catgatacta	agtatttgat	960
	aagtaccagg	aaacaggggt	tgtaatagtt	ctaacttttt	ttgacaattg	ctttgttttt	1020
	tctaaacttg	taatagatgt	aacaaaagaa	ataataataa	taatgcccgg	ggctttatta	1080
5	tgctatatca	ctgctcagag	gttaataatc	ctcactaact	atcctatcaa	atttgcaact	1140
	ggcagtttac	tctgatgatt	caactccttt	tctatctacc	cccataatcc	caccttactg	1200
	atacacctca	ctggttactg	gcaagatacg	ctggatccct	ccagccttct	tgctttccct	1260
	gcaccagccc	ttcctcactt	tgccctgccc	tcaaagctaa	caccacttaa	accacttaac	1320
	tgcaattctgc	cattgtgcaa	aagtctatga	aatgtttagg	tttcttttaa	ggatcacagc	1380
10	tctcatgaga	taacacccct	ccatcatggg	acagacactt	caagcttctt	tttttgtaac	1440
	ccttcccaca	ggtcttagaa	catgatgacc	actccccag	ctgccactgg	gggcagggat	1500
	ggtctgcaca	aggtctgggt	ctggctggct	tcacttccct	tgcacactcg	gaagcaggct	1560
	gtccattaat	gtctcggcat	tctaccagtc	ttctctgcca	acccaattca	catgacttag	1620
	aacattcgcc	ccactcttca	atgacccatg	ctgaaaaagt	ggggatagca	ttgaaagatt	1680
15	ccttcttctt	ctttacgaag	taggtgtatt	taattttagg	tcgaagggca	ttgcccacag	1740
	taagaacctg	gatgggtcaag	ggctctttga	gagggctaaa	gctgcgaatt	ctttccaatg	1800
	ccgcagagga	gccgctgtac	ctcaagacaa	cacctttgta	cataatgtct	tgctctaagg	1860
	tggacaaagt	gtagtcacca	ttaagaatat	atgtgccatc	agcagctttg	atggcaagaa	1920
	agctgccatt	gttcctggat	cccctctggg	tccgctgttt	cacttcgatg	ttgggtggctc	1980
20	cagttggaat	tgtgatgata	tcatgatatc	caggttttgc	actagtaact	gatcctgata	2040
	ttttttttaca	agtagatcca	tttccccgcg	aaacaccaca	tttatcaaac	ttcttttttg	2100
	agtctatgat	gcgatcacia	ccagctttta	caca			

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30	ggacaatttc	tagaatctat	agtagtatca	ggatatattt	tgcctttaaaa	tatatatttg	60
	ttattttgaa	tacagacatt	ggctccaaat	tttcatcttt	gcacaatagt	atgacttttc	120
	actagaactt	ctcaacattt	gggaactttg	caaatatgag	catcatatgt	gttaaggctg	180
	tatcatttaa	tgctatgaga	tacattgttt	tctccctatg	ccaaacaggt	gaacaaacgt	240
35	agttgttttt	tactgatact	aaatgttggc	tacctgtgat	tttatagtat	gcacatgtca	300
	gaaaaaggca	agacaaatgg	cctcttgtac	tgaatacttc	ggcaaaactta	ttgggtcttc	360
	attttctgac	agacaggatt	tgactcaata	tttgtagagc	ttgcgtagaa	tggtattacat	420
	ggtagtgatg	cactggtaga	aatgggtttt	agttattgac	tcagaattca	tctcaggatg	480
	aatcttttat	gtctttttat	tgtaagcata	tctgaattta	ctttataaag	atgggttttag	540
40	aaagctttgt	ctaaaaattt	ggcctaggaa	tggttaacttc	attttccagt	gccaaggggt	600
	agaaaaataa	tatgtgtgtt	gttatgttta	tggttaacata	ttattaggta	ctatctatga	660
	atgtatttaa	atatttttca	tattctgtga	caagcattta	taatttgcaa	caagtggagt	720
	ccatttagcc	cagtgggaaa	gtcttggaac	tcaggttacc	cttgaaggat	atgctggcag	780
	ccatctcttt	gatctgtgct	taaactgtaa	tttatagacc	agctaaatcc	ctaacttga	840
45	tctggaatgc	attagttatg	ccttgtacca	ttcccagaat	ttcaggggca	tcgtgggttt	900
	ggtctagtga	ttgaaaacac	aagaacagag	agatccagct	gaaaaagagt	gatcctcaat	960
	atcctaacta	actggtcctc	aactcaagca	gagtttcttc	actctggcac	tgtgatcatg	1020
	aaacttagta	gaggggattg	tgtgtatttt	atacaaat	aatacaatgt	cttacattga	1080
	taaaattctt	aaagagcaaa	actgcatttt	atctctgcat	ccacattcca	atcatattag	1140
50	aactaagata	tttatctatg	aagatataaa	tggtgcagag	agactttcat	ctgtggattg	1200
	cgttggtttct	tagggttcct	agcactgatg	cctgcacaag	catgtgatat	gtgaaataaa	1260
	atggattctt	ctatagctaa	atgagttccc	tctggggaga	gttctgggtac	tgcaatcaca	1320
	atgccagatg	gtgtttatgg	gctattttgt	taagtaagt	gtaagatgct	atgaagtaag	1380
	tgtgtttgtt	ttcatcttat	ggaaactctt	gatgcatgtg	cttttgtagt	gaataaattt	1440
55	tggtgcaata	tgatgtcatt	caactttgca	ttgaattgaa	ttttgggtgt	atttatatgt	1500
	attataacctg	tcacgcttct	agttgcttca	accattttat	aaccattttt	gtacataatt	1560
	tacttgaaaa	tatttttaaat	ggaaatttaa	ataaacattt	gatagtttac	ataataaaaa	1620
	aaaaaa						

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65	gttcagcatt	gtttctgctt	ctgaaatctg	tatagtacac	tggtttgtaa	tcattatgtc	60
----	------------	------------	------------	------------	------------	------------	----

5	ttcattgaaa	tccttgctac	ttctcttcc	cctcaatgaa	agacacgaga	gacaagagcg	120
	acacaagctt	aagaaaaacg	agcaaggaag	agtatcttca	ttattctcat	tttctctgag	180
	ttggaaacaa	aaacatgaag	gactccaact	agaagacaga	tattttacatt	taaatagatt	240
	agtgggaaaa	ctttaagagt	ttccacatat	tagtttttcat	tttttgagtc	aagagactgc	300
	tccttgtaact	gggagacact	agtagtatat	gtttgtaatg	ttacttttaa	attatctttt	360
	tattttataa	ggcccataaa	tactgggttaa	actctgttaa	aagtgggcct	tctatcttgg	420
	atggtttcac	tgccatcagc	catgctgata	tattagaaat	ggcatcccta	tctacttact	480
	ttaatgctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgggtg	540
	tcagccttgc	catgtatcag	tttcacttga	aatttgagac	caattaaatt	tcaactgttt	600
	aggggtggaga	aagagggtact	ggaaaacatg	cagatgagga	tatcttttat	gtgcaacagt	660
10	atccttttgca	tgggaggaga	gttactcttg	aaaggcaggc	agcttaagtg	gacaatgttt	720
	tgtatatagt	tgagaatttt	acgacacttt	taaaaattgt	gtaattgtta	aatgtccagt	780
	tttgctctgt	tttgccctgaa	gttttagtat	ttgttttcta	ggtggacctc	tgaaaaccaa	840
	accagtacct	ggggagggtta	gatgtgtgtt	tcaggccttg	agtgtatgag	tggtttttgc	900
	tgtatttttcc	tccagagatt	ttgaacttta	ataattgcgt	gtgtgttttt	ttttttttta	960
	gtggcctttgt	ttttttttct	caagtaaaat	tgtgaacata	tttcctttat	aggggcaggg	1020
	catgagtttag	ggagactgaa	gagtattgta	gactgtacat	gtgccttctt	aatgtgtttc	1080
	tcgacacatt	ttttttcagt	aacttgaaaa	ttcaaaaggg	acatttggtt	aggttactgt	1140
	acatcaatct	atgcataaat	ggcagccttg	tttcttgagc	cactgtctaa	attttgtttt	1200
	20	tatagaaatt	ttttatactg	attgggttcat	agatggtcag	ttttgtacac	agactgaaca
atacagcact	ttgccaaaaa	tgagtgtagc	attgttttaa	cattgtgtgt	taacacctgt	1320	
tctttgtaat	tgggttgtgg	tgcattttgc	actacctgga	gttacagttt	tcaatctgtc	1380	
agtaaataaa	gtgtccctta	acttcaaaaa	aaaaaaaaaa				
25	<210>	26					
	<211>	689					
	<212>	DNA					
	<213>	Human					
30	<400>	26					
35	aaacaaacaa	aaaaaaagtt	agtactgtat	atgtaaatac	tagctttttca	atgtgctata	60
	caaacaatta	tagcacatcc	ttcctttttac	tctgtctcac	ctccttttagg	tgagtacttc	120
	cttaaataag	tgctaaacat	acatatacgg	aacttgaaag	ctttgggttag	ccttgcccta	180
	ggtaatcagc	ctagttttaca	ctgttttccag	ggagtagttg	aattactata	aaccatttagc	240
	cacttgctctc	tgcaccatttt	atcacaccag	gacaggggtct	ctcaacctgg	gcgctactgt	300
	catttggggc	caggtgatcc	ttccttgcaa	gggctgtcct	gtacctgcc	gggcgggccgc	360
	tcgaagcgtg	gtcgcggccg	aggtactgaa	aggaccaagg	agctctggct	gccctcagga	420
	attccaaatg	accgaaggaa	caaagcttca	gggctctggg	tgggtgtctcc	cactatttcag	480
	gaggtggctg	gaggtaacgc	agcttcattt	cgtccagtc	tttccagtat	ttaaagtgtg	540
	40	tgtcaagatg	ctgcatttaa	tcaggcaggt	ctacaaaggc	atcccaagca	tcaaacatgt
ctgtgatgaa	gtaatcaatg	aaacaccgga	acctccgacc	acctcctgaa	tagtgggaga	660	
cacaccacaga	gcctgaagtt	tgtccttcg					
45	<210>	27					
	<211>	471					
	<212>	DNA					
	<213>	Human					
50	<400>	27					
55	tcccagcggc	atgaagtttg	agattggcca	ggccctgtac	ctgggcttca	tctccttcgt	60
	ccctctcgct	cattgggtggc	accctgcttt	gcctgtcctg	ccaggacgag	gcaccctaca	120
	agccctaacc	caggccccgc	ccagggccac	cacgaccact	gcaaacaccg	cacctgccta	180
	ccagccacca	gctgcctaca	aagacaatcg	ggccccctca	gtgacctcgg	ccaccacagc	240
	gggtacaggc	tgaacgacta	cgtgtgagtc	cccacagcct	gcttctcccc	tgggctgctg	300
	tgggctgggt	cccggcggga	ctgtcaatgg	aggcaggggt	tccagcacaa	agtttacttc	360
	tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgtctt	tagagcacag	420
	60	ggacagaggg	ggaaataaga	ggaggagaaa	gctctctata	ccaaagactg	a
65	<210>	28					
	<211>	929					
	<212>	DNA					
	<213>	Human					
<400>	28						

	ggtgaactca	gtgcattggg	ccaatgggttc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acggtttggc	tgctgggtggg	ctttcccctc	actgtcattg	gaggcacctt	120
5	tgggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
	gattccaccc	cagccctggt	acaagtctac	tgcatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tggagctgta	ctacatcttt	gccacagtat	ggggtcggga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgcactca	cctacttcca	gttgctctggg	gaggattacc	gctgggtggg	420
10	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcate	ttcctctact	cagttttcta	480
	ttatgcccg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttcctcat	gctgggcacc	atctcctttt	tttcttccct	600
	aaagtctcat	cggatatatc	atgttaacct	caagatggac	tgagtctctg	atggcagaac	660
	tattgctgtt	ctctcccctt	cttcatgccc	tgttgaactc	tcctaccagc	ttctcttctg	720
15	attgactgaa	ttgtgtgatg	gcattgttgc	cttccccttt	tccttttggg	cattcccttc	780
	ccagagaggg	cctggaaatt	ataaatctct	atcacataag	gattatatat	ttgaactttt	840
	taagttgcct	ttagtttttg	tcctgatttt	tctttttaca	attaccaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
20	<210> 29						
	<211> 1775						
	<212> DNA						
	<213> Human						
25	<400> 29						
	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaatgt	ccgaagggat	tttggccaac	60
	accagaaaac	gccaatgtcc	taggaattcc	ctcccaaaat	gcttcccaaa	aaattactca	120
	ttgacaattc	aaattgcact	tggctggcgg	cagcccgggc	ggccttcagt	ccgtgtgggg	180
30	cgcccgcgtg	gccttctcct	cgtaggactc	cccaaactcg	ttcactctgc	gtttatccac	240
	aggataaagc	caccgctggt	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccggtga	gacgtgggca	tggatgatg	gaaggcaaag	acgtcatcaa	tgaaggtgtt	360
	gaaagccttg	taggtgaagg	ccttccaggg	cagatgtgcc	actgacttca	acttgtagtt	420
	cacaaagagc	tggggcagca	tgaagaggaa	accaaaggca	tagaccccgt	tgacgaagct	480
35	gttgattaac	caggagtacc	agctcttata	tttgatattc	aggagtgaat	agacagcacc	540
	cccgcacacg	agaggggtaca	gcaggatga	caagtacttc	atggcctgag	tatcgtactc	600
	ctcgggtttt	ctctcagatt	cgctgtaagt	gccaaactga	aattcggggc	tcaggcctct	660
	ccaaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggctccaac	720
	accgcgccgg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
40	cacgggtgctg	aagcagcgcc	agagcactgc	cttgggtggac	atgccgatca	tgctcttctt	840
	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaa	aaggtcagcg	ccagggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tcttttctctg	aaaacccgaa	ctgctgcagg	gagtacacgg	cgctcctgcat	1020
	gtggatccag	aagcgcagcc	gccccagtga	gaccttgctg	taggacacgg	tgaggggcag	1080
45	ctcgggtggtg	gagcggttta	tgaccatcag	gtccttcacg	cggttgctga	gctggctgat	1140
	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcggca	ggcagggagg	acccgtcaaa	gacaaagtgt	tcgcgccatca	cgttcagcgc	1260
	cagccgcggg	cgccagtggg	acactggctc	atccagggca	ctcgtcgggt	tcttctccgc	1320
	ctcgatctgc	tgtgtatcag	actccccggg	gagcaggttg	atttcttctg	gcttggggac	1380
50	catgtagggtg	gtcagaggac	tgaccagggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
	cccagcgtga	tggaggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttcttttg	1500
	tacagaaaca	ttaactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccaggtcg	atgtttgttct	cagcaccacg	gtgggacctc	gtcgtgggtg	acacgctcag	1620
	ctgcagcttg	ggccgcgcgc	ccaggtaggg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
55	gcgggtgtag	acgatgccgt	acatgacca	gcagggtgtg	accacgtaga	ccacgaacac	1740
	gcccaccacc	aagctgggtga	aggagctgcg	gcccc			
60	<210> 30						
	<211> 1546						
	<212> DNA						
	<213> Human						
	<400> 30						
65	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgacca	ttcttttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaca	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaaa	acctcacagt	ctcaagtaat	aggcactgag	660
10	gggtgaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccc	720
	gtgggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctgggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgaact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaatttttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
20	actttcctta	atgttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aatcataacc	atgctacttt	1440
	gtacatatata	gtatttttatt	cctgctttcg	tggtactttt	aataaataac	tactgtactc	1500
	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
25	<210> 31						
	<211> 750						
	<212> DNA						
	<213> Human						
30	<400> 31						
	cacttgggca	cccccatttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
35	atagcaaata	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatattc	tggtttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgctttttaca	420
40	gtggcaagcc	aatttttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactattttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccata	ggctcttgtaa	aaaggaagtc	tgaatacaga	gcccaacaac	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatacatca	cacagacacg	atttggactc	cctgacaggt	660
	ggattggaaa	acgggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
45	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210> 32						
	<211> 1620						
	<212> DNA						
50	<213> Human						
	<400> 32						
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggatcc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgtttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtccctt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
65	tgagattgtg	cacaaaaatt	aggtcatgcc	ttcagtgtct	tggttcttta	acctaccctt	720
	tgacaatcag	gtgctaataga	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

5	gtgttcctcc	taggttggaa	gaaatgtctt	tcctttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
	tcgcaaactc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
10	aaatctgtcc	tttttggtag	caaacctgag	gtctttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcaaactct	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
	atttaaacia	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
15	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggtattat	atatataaat	1560
	acatatatac	ctttgttaacc	tttataactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210> 33						
20	<211> 2968						
	<212> DNA						
	<213> Human						
	<400> 33						
25	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
30	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
	gtacttgggc	atgtggacac	agggagagaa	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
35	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttgagagccc	660
	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgactct	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
40	acttttgtgt	ctttggtagc	tacctctgca	catactgggtg	atggcatggg	aagtctgatc	960
	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaaa	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttccttg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctcttc	ctatgaagga	attacgagtg	1200
45	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	aggggggtaaa	gattcttgga	1260
	aaagacctgg	agaaaacatt	ggctgggttta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
50	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagtgt	aggagttaga	1620
	attttttagt	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaattttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtggaa	1800
55	gcaggtcagg	tgaaacaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtccattga	tgactcaaaa	2040
	gactgggtca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
60	gtatttgaaa	tcacttaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tgggaaggag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgtttttaag	tttgcccttc	2400
65	cccaaatttg	gattttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattctttg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttcccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

15

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
 tgatecggtt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

20 acggggcgcc ggacgacccg cacatcttat cctccacgcc ccaactcgcac tcggagcggg 60
 accgccccgg actccccctc gggcgcggcca ctcgaggagt gaggagagag gccgcgggcc 120
 cggcttgagc cgagcgcagc accccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctctgtgggt cggggtcgcg cggccgcaga aggggcgggg 300
 tccgccccgc aggggaggcg cccccgggga cccgagaggg gggtaggac cgcgggctgc 360
 25 tgggtgcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccc 420
 gctgcgagga ggaggcggcg gcggcgcagg aggatgtact tggtaggggg ggacaggggg 480
 ttggccggct gcgggcacct cctgggtctcg ctgctggggc tgctgctgct gccggcgcgc 540
 tccggcaccc gggcgctggg ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgccccg ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgcagccag 660
 30 gggaacgaga gctgcggcgg caccttcggg atttacgaa cctgcgaccg ggggctgcgt 720
 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg cttgggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960
 35 gagaagccag attgctccaa ggcccgcgtg gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgttac tttgccaaca 1320
 agatgcgagt gtctctctgg cttatgtggg ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtggcg tgggacacct ggaaagtgtc gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcacccgc 1560
 45 cagtgtgggt agataaactg cgagagggtac tacgtgcccg aaggagagtg ctgcccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgcaa tggcctgatc 1680
 cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatgggtt caaacgcgat 1920
 50 cacaatgggt gtccgacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggg ttccctactg atgccccaaa ctgtgagatc 2040
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220
 55 tgcaagtgca gagaggcctc tgcttcagct gggccacca tcctgtcggg cacttgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2400
 aaccccacca ttcaccctgg acagtgtgtc ccatcatgtg cagatgactt tgtgggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
 60 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640
 tgctgcccac agtgtacaga tcaacctttt cggccttctt tgtcccgcaa taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 gacgtttgta ccagctgcat ctgcattgat agcgtaatta gctgtttctc tgagtcctgc 2820
 65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgtcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtgggtgtc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgacggggcca	gaccctctgc	3000
	tgcaccgtca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagagggttga	cctggagggtt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgtccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctta	ttataatage	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccagggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
15	atgtgcagaa	caagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
	ccaaagtttt	taaagttgct	aagatatatt	tgctgtgaag	atagctgtag	agatatttgg	3840
	gggtggggaca	gtgagtttgg	atggggaaag	gggtggggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggg	aacataaaaag	cagttcagtg	gcccagagggt	3960
	tatttttttt	ctattgctct	gaagactgca	ctgggttctg	caaagctcag	gcctgaatga	4020
20	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
	agcacatcag	aaccctttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcacaac	tgcagtaggc	agtgaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttatatt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
25	atgtgagcac	tggagctttt	ttttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggttgctttg	ttctgttata	4440
	ttgtttggtt	ttcatagtgt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgattc	tacaaaatag	aaactacttc	4560
	attttaattg	tataattatc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
30	aaacttttagc	aattatagga	gtatttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttctct	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
35	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attcctttat	taaaatcttc	ctcattttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatacct	aatcagctcc	tggttttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtt	tagtatgcct	caaataatac	tgactgtata	ctatagtggg	aacttttcaa	5220
40	acagccctta	gcacttttat	actaattaac	ccattttgtg	attgagtttt	cttttaaaaa	5280
	tgcttggtgt	gaaagacaca	gatacccagt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaataacttg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	atattattatt	ataatgacct	aattttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aagggtgttct	agctgttttg	atcaaaggaa	5520
45	aaaaagattt	attatcaagg	ggcaatatatt	ttatcttttc	caaaataaat	ttgttaatga	5580
	tacattacaa	aatagatttg	acatcagcct	gatttagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttggttttt	5700
	caatcatggc	catattatga	aaataactaac	aggatatagg	acaagggtga	aatttttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttacttttgt	5820
50	tcctgttggt	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaaat	agatatatgg	5880
	cacttgaggt	gcatacatag	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

65	mylvagdrgl	agcghllvsl	lglllllpars	gtralvclpc	deskceprn	rpgsivqgvc	60
	gccytcasgg	nescgggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpge	240

5 ccdlyeckpv fgvdcrctvec ptvqqtacpp dsyetqvrlt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfrr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctltrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgcl icrckkkpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpggqccp 660
 scaddfvvqk pelstpsich apggeyfvveg etwnidsctq ctchsgrvlc etevcppllc 720
 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
 10 viscfesescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscthc 840
 yclqggqtlcs tvscpplpcv epinvegscs pmcpemyvpe ptnipiektn hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiiic lsiiiaflfi 960
 nqkkqwipll cwyrtpkps slnnqlvsvd ckkgtrvqvvd ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtacctg gagtgtcctg caggggggaaa gcgaaccggg ccctgaagtc cgggggcagtc 60
 acccggggct cctggggccgc tctgcccggg tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatattt acagattgag aaactatggt tcaagaagag aggacggggc 300
 30 ttgagggaat ctcttgattc tccttatatg acctcaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggg ttctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggg cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag gggttaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36

<211> 395

<212> DNA

40 <213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaa accaaagtca gggttaacaa tgtcatttta caaatgtta aaaccctaata 300
 50 tgcagttcct tttttaaatt atttttaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

<212> DNA

55 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggccatca acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38

65 <211> 644

<212> DNA

<213> Human

<400> 38

```

5  aagcctggtt  tcatggggga  ggtggtggcg  cttggtggcc  actggcgggc  gaggtagagg  60
   cagtggcgct  tgagttggtc  gggggcagcg  gcagatttga  ggcttaagca  acttcttccg  120
   gggaagagtg  ccagtgcagc  cactgttaca  attcaagatc  ttgatctata  tccatagatt  180
   ggaatatttg  tgggccagca  atcctcagac  gcctcactta  ggacaaatga  ggaaactgag  240
   gcttggtgaa  gttacgaaac  ttgtccaaaa  tcacacaact  tgtaaagggc  acagccaaga  300
10  ttcagagcca  ggctgtaaaa  attaaaatga  acaaattacg  gcaaagtttt  aggagaaaga  360
   aggatgttta  tgttccagag  gccagtcgtc  cacatcagtg  gcagacagat  gaagaaggcg  420
   ttcgcaccgg  aaaatgtagc  ttcccgggta  agtaccttgg  ccatgtagaa  gttgatgaat  480
   caagaggaat  gcacatctgt  gaagatgctg  taaaagatt  gaaagctgaa  aggaagttct  540
   tcaaaggctt  ctttggaaaa  actggaaaga  aagcagttta  agcagtttct  gtgggtctaa  600
15  gcagatggac  tcagagggtg  tggatgaaaa  actaaggacc  tcat

```

<210> 39

<211> 657

<212> DNA

<213> Human

<400> 39

```

25  ctttttgttt  gggttttcca  atgtagatgt  ctcagtgaag  tgtgcagata  tactttgttc  60
   cttatatggt  caccagtgtt  aattatggac  aaatacatta  aaacaagggt  tcctggccca  120
   gcctcccata  taatctcttt  gatactcttg  gaatctaagt  ctgaggagcg  atttctgaat  180
   tagccagtgt  tgtaccaact  ttctgttagg  aattgtatta  gaataacctt  tctttttcag  240
   acctgctcag  tgagacatct  tggggaatga  agtaggaaaa  tagacatttg  gtggaaaaac  300
   agcaaaatga  gaacatttaa  aagactcatt  caagtatgag  tataaagggc  atggaaattc  360
30  tggtcctttg  agcaaaatga  gaagaaaaaa  ttctgctcag  cagtattcac  tgtgttaaga  420
   ttttttgttt  tttacacgaa  tggaaaaaatg  atgtgttaagt  ggtatagatt  ttaatcagct  480
   aacagtcact  ccagagatgt  tgatcagcac  caattcctat  agtagtaagt  atttaaaagt  540
   taagaaatac  tactacattt  aacattataa  agtagagtgc  tggacataac  tgaaaattag  600
   atgtttgctt  caatagaaat  ttgttcccac  ttgtattttt  aacaaaatta  tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

```

45  acaattttta  aataactagc  aattaatcac  agcatatcag  gaaaaagtac  acagtgagtt  60
   ctgggttagt  tttgtaggct  cattatgggt  agggtcgtta  agatgtatat  aagaacctac  120
   ctatcatgct  gtatgtatca  ctcatcccat  ttcatgttc  catgcatact  cgggcatcat  180
   gctaatatgt  atccttttta  gcactctcaa  ggaaacaaaa  gggcctttta  tttttataaa  240
   ggtaaaaaaa  attccccaaa  tattttgcac  tgaatgtacc  aaagggtgaag  ggacattaca  300
   atatgactaa  cagcaactcc  atcacttgag  aagtataata  gaaaatagct  tctaaatcaa  360
   acttccttca  cagtgccgtg  tctaccacta  caaggactgt  gcatactagt  aataattttt  420
50  taagattcac  tatatgtgat  agtatgatat  gcatttattt  aaaatgcatt  agactctctt  480
   ccatccatca  aatactttac  aggatggcat  ttaatacaga  tatttcgtat  ttccccact  540
   gctttttatt  tgtacagcat  cattaaacac  taagctcagt  taaggagcca  tcagcaacac  600
   tgaagagatc  agtagtaaga  attccatttt  ccctcatcag  tgaagacacc  acaaattgaa  660
   actcagaact  atatttctaa  gcctgcattt  tcatgatgc  ataattttct  tagtaatatt  720
55  aagagacagt  ttttctatgg  catctccaaa  actgcatgac  atcactagtc  ttacttctgc  780
   ttaattttat  gagaagggtat  tcttcatttt  aattgctttt  gggattactc  cacatctttg  840
   tttatttctt  gactaatcag  attttcaata  gagtgaagtt  aaattggggg  tcataaaaagc  900
   attggattga  catatgggtt  gccagcctat  gggtttacag  gcattgacca  aacatttctt  960
   tgagatctat  atttataagc  agccatggaa  ttctatttat  gggatgttgg  caatcttaca  1020
60  ttttatagag  gtcatatgca  tagttttcat  aggtgttttg  taagaactga  ttgctctcct  1080
   gtgagttaag  ctatgtttac  tactgggacc  ctcaagagga  ataccactta  tgttacactc  1140
   ctgcactaaa  ggcacgtact  gcagtgtgaa  gaaatgttct  gaaaaagggt  tatagaaatc  1200
   tggaaataag  aaaggaagag  ctctctgtat  tctataattg  gaagagaaaa  aaagaaaaac  1260
   ttttaactgg  aaatgttagt  ttgtacttat  tgatcatgaa  tacaagtata  tatttaattt  1320
65  tgaaaaaa

```

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
taacccccgg ctatcagtcg ggatgggttg caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcatg 360
15 aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420
ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccctttttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
20 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
aatagtctac ggccatacca ccctgaacgt gcctaatact gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaataactt gttgaataaa 960
25 tgaagtagcg atttgggtgtg aaaaaaa

<210> 42
<211> 956
<212> DNA
<213> Human

30

<400> 42

35 cggacgggtg ggcggacgcg tgggtgcagg agcaggggcg ctgccgactg ccccaaccaa 60
ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300
cacgcacctc cacgccactg cctcccccg aatgcatttg aaccaaagtc taaactgagc 360
40 tcgcagcccc cgcgccctcc ctccgcctcc catcccgtt agcgtctctg acagatggac 420
gcaggccctg tccagcccc agtgcgctcg ttccgggtccc cacagactgc cccagccaac 480
gagattgctg gaaaccaagt caggccagggt gggcggacaa aaggggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcgggtg 600
gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
tgaattaat cagatgtttt acgcaaggaa ggacttacc agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgggtg accccatcac 780
tcgcaggacc aagggggcg ggactgctgg ctacgcctcc gctgtgtcct cctccctc 840
ccttccttgg gcagaatgaa ttcatgctg attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

<210> 43
<211> 536
<212> DNA
<213> Human

55

<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaagtgtt aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtctttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
65 aggggtggtt ccccggcacc tggacctgga caggtagggg tccgtgggtt accagt

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

10	ggggagggac	gagtatggaa	ccctgaaggt	agcaagtcca	ggcactggcc	tgaccatccg	60
	gctccctggg	caccaagtcc	caggcaggag	cagctgtttt	ccatcccttc	ccagacaagc	120
	tctatttttta	tcacaatgac	cttttagagag	gtctcccagg	ccagctcaag	gtgtcccact	180
	atccccctctg	gaggggaagag	gcaggaaaat	tctccccggg	tccctgtcat	gctactttct	240
	ccatcccagt	tcagactgtc	caggacatct	tatctgcagc	cataagagaa	ttataaggca	300
	gtgatttccc	ttaggcccag	gaattggggc	tccagctcat	ctgttccttc	tgggcccatt	360
	catggcaggt	tctgggctca	aagctgaact	ggggagagaa	gagatacaga	gctaccatgt	420
15	gactttacct	gattgccctc	agtttggggg	tgcttattgg	gaaagagaga	gacaaagagt	480
	tacttgttac	gggaaatatg	aaaagcatgg	ccaggatgca	tagaggagat	tctagcaggg	540
	gacaggattg	gctcagatga	cccctgaggg	ctcttccagt	cttgaaatgc	attccatgat	600
	attaggaagt	cgggggtggg	tggtggtggg	gggctagttg	ggtttgaatt	taggggcca	660
	tgagcttggg	tacgtgagca	gggtgttaag	ttagggtctg	cctgtatttc	tgggtcccctt	720
20	ggaaatgtcc	ccttcttcag	tgtcagacct	cagtcccagt	gtccatatcg	tgcccagaaa	780
	agtagacatt	atcctgcccc	atcccttccc	cagtgcactc	tgacctagct	agtgcctggg	840
	gcccagtgac	ctgggggagc	ctggctgcag	gccctcactg	gttccctaaa	ccttggtggc	900
	tgtgattcag	gtccccaggg	gggactcagg	gaggaatatg	gctgagttct	gtagtttcca	960
	gagttggctg	gtagagcctt	ctagaggttc	agaatattag	cttcaggatc	agctgggggt	1020
25	atggaattgg	ctgaggatca	aacgtatgta	ggtgaaagga	taccaggatg	ttgctaaagg	1080
	tgagggacag	tttgggtttg	ggacttacca	gggtgatgtt	agatctggaa	cccccaagtg	1140
	aggctggagg	gagttaaggt	cagtatggaa	gatagggttg	ggacagggtg	ctttggaatg	1200
	aaagagtgac	cttagagggc	tccttgggcc	tcaggaatgc	tcctgctgct	gtgaagatga	1260
	gaaggtgctc	ttactcagtt	aatgatgagt	gactatatct	accaaagccc	ctacctgctg	1320
30	ctgggtccct	tgtagcacag	gagactgggg	ctaaggggcc	ctcccaggga	agggacacca	1380
	tcaggcctct	ggctgaggca	gtagcataga	ggatccattt	ctacctgcat	ttcccagagg	1440
	actagcagga	ggcagccttg	agaaaccggc	agttcccaag	ccagcgcctg	gctgttctct	1500
	cattgtcact	gccctctccc	caacctctcc	tctaaccac	tagagattgc	ctgtgtcctg	1560
35	cctcttgcc	cttgtagaat	gcagctctgg	ccctcaataa	atgcttctctg	cattcatctg	1620
	caaaaaaaaa						

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

45	tctttttgctt	ttagctttttt	attttttgtat	taacaggagt	cttattacac	ataggtctga	60
	taaaactggt	ttatgatctt	cagtctgatt	ccagtgtctg	ataactagat	aacgtatgaa	120
	ggaaaaacga	cgacgaacaa	aaaagtaagt	gcttggaaga	cttagttga		

<210> 46
 <211> 769
 <212> DNA
 <213> Human

50

<400> 46

55	tgcaggctcat	atcttactatc	ggcaataaaa	ggaagcaaag	cagtattaag	cagcgggtgga	60
	atcttgctgct	ttcactttttt	ataaagtgtc	acataaaaatg	tcatattttcc	aaatttataaa	120
	acataactcc	agttcttacc	atgagaacag	catgggtgatc	acgaaggatc	ttcttgaaaa	180
	aaacaaaaaac	aaaaacaaaa	aacaatgatc	tcttctgggt	atcacatcaa	atgagataca	240
	aagggtgtact	aggcaatctt	agagatctgg	caacttatctt	tatatataag	gcactctgtga	300
60	ccaagagacg	ttatgaatta	aatgtacaaa	tgtattatgt	ataaatgtat	taaatgcaag	360
	cttcatataa	tgacaccaat	gtctctaatg	tgctcagaga	tcttgactgg	ctgtggccct	420
	ggccagctcc	tttcttgata	gtctgattct	gccttcatat	ataggcagct	cctgatcatc	480
	catgccagtg	aatgagaaaa	caagcatgga	atatataaac	tttaacatta	aaaaatgttt	540
	tattttgtaa	taaaatcaaa	tttcccattg	aaaccttcaa	aaactttgca	gaatgaggtt	600
65	ttgatatatg	tgtacaagta	gtaccttctt	agtgcagaa	aacatcatta	tttctgtctg	660
	cctgcctttt	tgttttttaa	aatgaagact	atcattgaaa	caagtttgtc	ttcagtatca	720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 ttttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
 gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcc acaaggggtg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatgggtgg aaggggggct cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 15 gccttactta gctcctggca gaggggtgagt ggggacctac gaggttcaaa atcaaattggc 360
 atttggccag cctggccttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
 tgggctcact ccatttccatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtctt ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660
 ggtgccccagg aatgttttaa atctatcagg cacactataa agctgggtgg ttcttcctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcatc ttcctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtgt 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttgggggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tccctacctgc ttggtacct agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttcccctc gattccacag 1200
 30 gaggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440
 gcagttgggc tgacctgaca aagccccag tttcctgtgg caggttctgg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacagg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 ctctcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagcttttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtggt gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
 45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggg gtcacccatg agagatgact caatgccaaag 2220
 gcctgaagtt atagagtgtt tacagcgggtg gcgatattca ggggtcatcg ccaactggtc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcataatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctagccaggc ccgttttcca tccctaagta ccattctctc atttgggcc ttctagggtt 240
 65 ggggccctga gcttgggttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggacgcgctc ttttcttttt ttttcctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcage cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt ttttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgctcctg acttttgtgat ccgcccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgtgtctg ggggtgtctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaagg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatgggt caggcaggga agggagctga agtgattcgg ggctaattgc 1380
 tcagatcgat gtatttctct cctgggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 20 tacgagaccg ggggtagcgt gatctcctgc ttccttgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtgggtccc agctactcag gaggtctgagg cgggaggatt gcttgagccc aggagttgga 60
 tgttgacagt agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccattgggaa cctggccaca 300
 35 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tgggggtggag 360
 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatg ggcaagcatg 420
 tgcgtgcctg tgtgtgtgctg tgcccctccc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag accttccct ggacctgggg gtctcgccgt atctcatgac 600
 cagggtgctaa atgaccgac atgcacacc tgcccttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtgta cctgcccccg tggcgtctca cggatgatgc tgctcctgac attgggtgtt 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840
 tactttgacc tcttgccctac aacccttcc ttgggtccga ggctggtagc tttgttccact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac tcccatgtgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	cgggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggtggctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
5	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcgga	gacgctcctg	acaagtcggg	360
	aattttctcta	tttctccact	ggtgcaaaga	gcggatttct	ccctgcttct	cttctgtcac	420
	ccccgctcct	ctcccccagg	aggctccttg	atztatggta	gctttggact	tgcttccccg	480
10	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gaggagagaa	tggttcttag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
15	aaaaagctga	actgcaaate	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tgagagaaagt	acagttctgt	1080
20	cttccaatac	ctctggccat	cagatgactt	taaaagggtac	aggagtaaaa	gtttaagatg	1140
	atggggcaaaa	gtccagtgtg	ttcagtaaag	tgctaatacac	aagttggagg	t	

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30	aacagggact	ctcactctat	caaccccagg	ctggagtcgg	gtgcgcccac	cctggctccc	60
	tgcaacctcc	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	tttttgtaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcagggttg	tttaaaaaata	attgcttttt	tattattttt	gcatttttgc	300
35	accaacctta	atgctatgta	aatagttggt	atactgttgc	ttaacaacag	tatgacaatt	360
	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtgt	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggctggct	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagttatgg	tacagtggaa	agagtagttg	aaaacataaa	catttggacc	600
40	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaaagaact	ggatactctc	taaggctcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaatgtgt	tctcttagaa	agctcaacta	aatttgagaa	900
45	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
	agagatgggg	tctcactctg	tcacccagac	tgagtagacg	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgate	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	tttttttaca	aatcagaaat	acttattttg	1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	catttatattt	60
	tatgcctttc	ttcctatgtg	tattttcaagt	cttttttcaaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tgccaggagtc	caggagacct	ctacaaatgc	180
	agagtgactc	tttaccacaa	ttaaccctag	atacatgcaa	aaagcaggac	ccttcctcca	240
	ggaatgtgcc	atttcagatg	cacagcaccc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcattg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
65	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttggtcaggc	ggtctcgaac	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

5	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aatttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aatcagttta	840
	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtgc	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccaccgcg				
10	<210> 54						
	<211> 250						
	<212> DNA						
	<213> Human						
15	<400> 54						
	catttcccca	ttggctcctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtgggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcaggga	180
20	aaagggcatt	cttttaggaac	tgcatctggt	aaccacacacc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210> 55						
	<211> 2270						
25	<212> DNA						
	<213> Human						
	<400> 55						
30	gcgcccccca	gcagcgcccg	cgcctctcgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggccgcgcgc	ccgccagcc	ctcgctccc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgcacggcct	gtccgctgca	caccagcttg	ttggcgctct	cgtegcgcgcg	180
	ctcgccccgc	gctaactcctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctcgctt	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tggcgctctc	cacctgcccc	gctgcctgcc	300
	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctccg	gacggctgcg	360
35	gctgctgtaa	ggtctgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gccaactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
	ttcctctgtg	tcccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggttg	660
	tcaaagttac	cgggcagtgc	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
40	ccatggagga	ccaggacggc	ctccttggca	aggagctggg	attcgatgcc	tccgaggttg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtcc	840
	ctgttttttg	aatggagcct	cgcctcctat	acaacccttt	acaaggccag	aatgtattg	900
	ttcaaacaac	ttcatgggtc	cagtgtctca	agacctgtgg	aactgggtatc	tccacacgag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
45	aatcccccca	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
	agtcctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcgttt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaa	gagtgtcaga	atcagaatca	tggagaaaat	gggcgggggt	1440
50	gggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
	ggatatttca	aactgccaag	ggtgctgggtg	cggatggaca	ctaattgcagc	cacgattgga	1560
	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcataattttc	tctaggcttt	1680
	tttccttttg	gggttctaca	gtcgtaaaag	agataataag	attagttgga	cagtttaaaag	1740
	ctttttattcg	tccttttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
55	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
	gggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttg	taaatgattt	taattttata	ttcagtgaag	agattttatt	1980
	tatggaatta	accattttaat	aaagaaatat	ttacctaata	tctgagtgtg	tgccattcgg	2040
	tattttttaga	ggtgctccaa	agtcattagg	aacaacctag	ctcacgtact	caattattca	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
60	ttataccttc	agtagagaaa	agtcctttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

<210> 56
 <211> 1636
 <212> DNA
 <213> Human

5

<400> 56

10	cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60
	agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
	cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg cttctctccc agatggctcc 180
	tggtttgctt ggtctcaagg acactgcatc gtcaaactga tcccctggcc gttggaggag 240
	cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
15	cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
	agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
	gatgtctctt gcctgggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
	gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
	agcttcacac ccagtggcag tttgatTTTT gtctccgcgt cacgggataa gactcttcgc 600
20	atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
	gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
	tcggctcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
	agcagtgttg tctcttTgtga cttctctccc gactctgccc tgcttgtcac ggcttcttac 840
	gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900
	accaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25	tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
	tggggccctgg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
	acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
	tggacagctc ctagggtcct gtcctcactg aagcacttat gccggaaagc ccttcgaagt 1200
30	ttcctaacia cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260
	acatacagga cttttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
	cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaaatagca 1380
	tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
	tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
35	aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
	aagatggtga agggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
	gaccctgtgc tgcgtt

<210> 57
 <211> 460
 <212> DNA
 <213> Human

40

<400> 57

45	ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
	gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
	tggaatgagc taaagcagcc gcctgggggtg ggaggccgag ccattttgta tgcagcaggg 180
	ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggggagct gagaccatcc 240
50	atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
	aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
	gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
	ccgagctcga attcgtaatc atgggtcatag ctgtttctctg

<210> 58
 <211> 1049
 <212> DNA
 <213> Human

55

<400> 58

60

65	atctgatcaa gaatacctgc cctggtcact ctgcggatgt ttctgtccac ttgttcacat 60
	tgaggaccaa gatatacttt ttacagagg cacttgcttc gtctaacaca gacacctcca 120
	tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gcctggacta 180
	cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
	gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
	ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360

5 aaaatgtaaa cttcacctag ttcattcttct ccaaatecca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgc ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtataca aatccaccaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccctg cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaataata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttgttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctggtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggetccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccctgtg ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaattta gtagtaatat cggccgc